TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor.
PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to
see how well it works in treating patients with advanced hepatocellular carcinoma (liver
cancer).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) Taiho Pharmaceutical Co., Ltd.